KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Accumulated Expenses: 2012-2024

Historic Other Accumulated Expenses for Emergent BioSolutions (EBS) over the last 8 years, with Dec 2024 value amounting to $27.7 million.

  • Emergent BioSolutions' Other Accumulated Expenses fell 64.35% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 64.35%. This contributed to the annual value of $27.7 million for FY2024, which is 15.29% down from last year.
  • Emergent BioSolutions' Other Accumulated Expenses amounted to $27.7 million in FY2024, which was down 15.29% from $32.7 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Other Accumulated Expenses high stood at $83.1 million for FY2020, and its period low was $27.7 million during FY2024.
  • Its 3-year average for Other Accumulated Expenses is $35.4 million, with a median of $32.7 million in 2023.
  • In the last 5 years, Emergent BioSolutions' Other Accumulated Expenses surged by 1,140.30% in 2020 and then slumped by 37.21% in 2022.
  • Emergent BioSolutions' Other Accumulated Expenses (Yearly) stood at $83.1 million in 2020, then fell by 12.03% to $73.1 million in 2021, then slumped by 37.21% to $45.9 million in 2022, then decreased by 28.76% to $32.7 million in 2023, then decreased by 15.29% to $27.7 million in 2024.